Using phenotypic screening to find new drugs to combat hypertrophic scarring, with Dr Alice Lapthorn

Join ARU's Medical Technology Research Centre (MTRC) for an online seminar from Dr Alice Lapthorn on our work to identify novel drugs using a high-throughput screening assay.

Although hypertrophic scarring affects ~91% of burn patients annually, there is no drug to prevent this common complication. Hypertrophic scars are a fibroproliferative disorder, caused by dysregulated wound healing. This can be characterised by persistent myofibroblast transformation and the excessive accumulation of extracellular matrix (ECM).

Our research has focussed on developing a high-throughput screening assay that utilises the myofibroblast phenotype, to identify novel drugs that could be repurposed as a therapeutic for the prevention of hypertrophic scarring.

Contact MTRC@aru.ac.uk for more information.